Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema

Takeda, Kazuhisa; Yamasaki, Akira; Igishi, Tadashi; Kawasaki, Yuki; Ito-Nishii, Shizuka; Izumi, Hiroki; Sakamoto, Tomohiro; Touge, Hirokazu; Kodani, Masahiro; Makino, Haruhiko; Yanai, Masaaki; Tanaka, Natsumi; Matsumoto, Shingo; Araki, Koji; Nakamura, Hiroshige; Shimizu, Eiji

doi:10.21873/anticanres.11375

Cited by 10 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Down regulation of c-Myc is associated with invasion/migration capacity of bronchial epithelial cells exposed to cigarette smoke extract 147 . EGFR 95 mutations act an oncogenic driver of lung cancer in non-smokers and light smokers 148 – 150 .…”

Section: Discussionmentioning

confidence: 99%

Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample

Cinciripini,

Wetter,

Wang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Despite the large public health toll of smoking, genetic studies of smoking cessation have been limited with few discoveries of risk or protective loci. We investigated common and rare variant associations with success in quitting smoking using a cohort from 8 randomized controlled trials involving 2231 participants and a total of 10,020 common and 24,147 rare variants. We identified 14 novel markers including 6 mapping to genes previously related to psychiatric and substance use disorders, 4 of which were protective (CYP2B6 (rs1175607105), HTR3B (rs1413172952; rs1204720503), rs80210037 on chr15), and 2 of which were associated with reduced cessation (PARP15 (rs2173763), SCL18A2 (rs363222)). The others mapped to areas associated with cancer including FOXP1 (rs1288980) and ZEB1 (rs7349). Network analysis identified significant canonical pathways for the serotonin receptor signaling pathway, nicotine and bupropion metabolism, and several related to tumor suppression. Two novel markers (rs6749438; rs6718083) on chr2 are flanked by genes associated with regulation of bodyweight. The identification of novel loci in this study can provide new targets of pharmacotherapy and inform efforts to develop personalized treatments based on genetic profiles.

show abstract

Section: Discussionmentioning

confidence: 99%

Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample

Cinciripini,

Wetter,

Wang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Importantly even in non-smoking patients, the EGFR mutation rate in patients with COPD was significantly lower than those without COPD ( p = 0.001). Another study led by Takeda et al showed 25% EGFR mutation in lung cancer without emphysema and 9% in those with emphysema [23]. As active EGFR mutation is the critical factor to predict the response and survival outcome for patients that underwent EGFR-TKI treatment, it is unsurprisingly that COPD patients might had poor treatment efficacy on EGFR-TKI because of inherited low EGFR mutation frequency [24].…”

Section: Discussionmentioning

confidence: 99%

Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study

Rau

Lee

et al. 2019

JCM

View full text Add to dashboard Cite

The emergence of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) caused a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). Although several clinicopathologic factors to predict the response to and survival on EGFR-TKI were recognized, its efficacy has not been confirmed for patients with underlying pulmonary disease, such as chronic obstructive pulmonary disease (COPD). We conducted the study to evaluate the impact of COPD on survival for NSCLC patients that underwent EGFR-TKI treatment. The nationwide study obtained clinicopathologic data from the National Health Insurance Research Database in Taiwan between 1995 and 2013. Patients receiving EGRR-TKI were divided into COPD and non-COPD groups, and adjusted for age, sex, comorbidities, premium level and cancer treatments. Overall survival (OS) and progression-free survival (PFS) were calculated by Kaplan–Meier analysis. In total, 21,026 NSCLC patients were enrolled, of which 47.6% had COPD. After propensity score (PS) matching, all covariates were adjusted and balanced except for age (p < 0.001). In the survival analysis, the median OS (2.04 vs. 2.28 years, p < 0.001) and PFS (0.62 vs. 0.69 years, p < 0.001) of lung cancer with COPD were significantly worse than those without COPD. Lung cancer patients on EGFR-TKI treatment had a worse survival outcome if patients had pre-existing COPD.

show abstract

“…But in cancer cells these two proteins experience changes characteristics due to changes in the structure of the constituent amino acids. 9 EGFR mutations include the type of point, deletion, and insertion mutations that occur most frequently on exons 18,29,20 and 21. 10 EGFR examination is one way to provide appropriate therapy for Non Small Cell Lung Carcinoma (NSCLC) sufferers.…”

Section: Introductionmentioning

confidence: 99%

Relationship of Various Characteristics of Lung Adenocarcinoma Patients with Status of Mutation of Epidermal Growth Factor Receptor (EGFR) In Haji Adam Malik Medan Hospital 2015-2017

Asrul¹,

Delyuzar²,

Soekimin³

2019

IJCTR

View full text Add to dashboard Cite

Lung cancer is a major cause of malignancy in the world, reaching up to 13% of all cancer diagnoses. In addition, lung cancer also causes 1/3 of all chemotherapy caused by cancer in men. Of the types of Non Small Cell Lung Carcinoma (NSCLC), pulmonary adenocarcinoma is the most common. Various characteristics of patients such as age, gender, occupation, ethnicity, smoking status and EGFR mutation status. This study was conducted to provide an overview of the distribution and frequency of all these characteristics, and find a relationship of various characteristics of adenocarcinoma patients based on gender, ethnicity and smoking status with EGFR mutation status in Haji Adam Malik General Hospital Medan 2015-2017. This research is descriptive-analytic with a cross sectional approach. Data on patient characteristics are obtained from medical records and cytology / histopatology images and the results of EGFR mutations have been examined and the results are known. In this study most of the patients were 55-64 years old. From the analysis of the relationship between sex with EGFR mutation status, p value = 0.043, analysis of the relationship between smoking status and EGFR mutation status, obtained p value = 0.040, while the analysis between the terms and mutation status obtained p value = 0.11.

show abstract

Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema

Cited by 10 publications

References 41 publications

Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample

Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample

Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study

Relationship of Various Characteristics of Lung Adenocarcinoma Patients with Status of Mutation of Epidermal Growth Factor Receptor (EGFR) In Haji Adam Malik Medan Hospital 2015-2017

Contact Info

Product

Resources

About